AAM’s Leonard On Strategizing For Gene Therapies
Low Biosimilars Approval A Concern
Executive Summary
As ‘hyper personalized’ medicines take hold, generic players need to examine the role they can play in democratizing access to gene therapies alongside complex generics and biosimilars, says AAM president and CEO Dan Leonard.
You may also be interested in...
Could US FDA User Fee Bill Include The Long-Sought 505(b)(2) Pathway For Biosimilars?
Former FDA official says the pathway is needed to avoid wasted sponsor time and effort.
Complex Generics: US FDA, Sponsors View Roadblocks Very Differently
As GDUFA III negotiations continue, FDA doesn’t seem ready to make additional changes to approval process, but industry argues guidance practices and communications need fixing and that consumers are missing out on potential savings because of it.
AAM’s Francer On Tackling Tactics That Hurt Market Access For Gx, Biosimilars
Association for Accessible Medicines interim CEO and general counsel Jeff Francer, in an interview with Scrip, discusses the industry body’s continued efforts to ensure that generics and biosimilars are not disadvantaged in the US by the brand name industry's commercial tactics or legal/regulatory moves, and outlines the 'enormous progress' made by generic firms on quality.